Personalis

Personalis R&D per Employee

The R&D Spending per Employee of Personalis (PSNL) as of Oct 12, 2026 is 194,069.50 USD. In the previous year, R&D Spending per Employee was 188,822.39 USD — a change of 2.78% (higher).

R&D per Employee

194,069.50USD

YoY

2.78%

Last updated:

R&D Spending per Employee of Personalis is 2025 194,069.50 USD. R&D Spending per Employee of Personalis was 2024 188,822.39 USD. It decreases by 2.78% higher compared to the previous year.

The Personalis R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
55,227.80 USD
Jan 1, 2019
86,555.98 USD
Jan 1, 2020
110,301.16 USD
Jan 1, 2021
190,393.82 USD
Jan 1, 2022
250,625.48 USD
Jan 1, 2023
250,100.39 USD
Jan 1, 2024
188,822.39 USD
Jan 1, 2025
194,069.50 USD
The Personalis R&D per Employee history
YEARR&D per EmployeeYoY
194,069.50USD+2.78%
188,822.39USD-24.50%
250,100.39USD-0.21%
250,625.48USD+31.64%
190,393.82USD+72.61%
110,301.16USD+27.43%
86,555.98USD+56.73%
55,227.80USD+44.21%
38,297.30USD—
Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

R&D Spending per Employee of Personalis is 194,069.50 USD in 2025.

R&D Spending per Employee of Personalis changed from 188,822.39 USD to 194,069.50 USD, representing a 2.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Personalis since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Personalis historically and in real time.

Access this data via the Eulerpool API

Workforce — Personalis

All Key Metrics — Personalis